Literature DB >> 10208622

Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients.

A Calebotta1, A M Sáenz, F González, M Carvalho, R Castillo.   

Abstract

BACKGROUND: Tetracycline is an antibiotic which has been proven beneficial as an immunomodulating drug in the treatment of autoimmune bullous diseases.
METHODS: Thirteen hospitalized patients with pempigus vulgaris received tetracycline 2 g/day for 1 month, then 1 g/day for the following 4 weeks. Prednisone 0.5-1 mg/kg/day was then gradually reduced. The control group consisted of seven patients with pemphigus who had received prednisone and azathioprine.
RESULTS: A total of 13 patients in the study group achieved cessation of new blister formation within 5.4 days, compared to 23.71 days (p < 0.0001). The average initial dose of prednisone was 76.53 mg/day for the study group and 118.57 mg/day in the control group (p < 0.014). The average number of days before reduction of the prednisone dosage could begin was 16.53 days for the study group compared to 31.28 days in the control (p < 0.049). Total hospitalization time was also significantly lower: 34.07 days (p < 0.001). The clinical response was not linked to the location of lesions nor to severity of disease.
CONCLUSIONS: Tetracycline was shown to be effective as an adjuvant therapy for pemphigus with low toxicity and safety.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208622     DOI: 10.1046/j.1365-4362.1999.00624.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  [Therapy resistant pemphigus vulgaris. Combination therapy with methylprednisolone and doxycycline].

Authors:  T Assmann; R Voss; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

2.  Topical application of Cassia fistula L. fruit gel in management of cutaneous lesions of pemphigus vulgaris: A double-blind, placebo-controlled clinical trial.

Authors:  Fatemeh Atarzadeh; Mohammad Kamalinejad; Gholamreza Amin; Alireza Salehi; Ladan Dastgheib; Amir Mohammad Jaladat; Mojtaba Heydari; Zahra Gouyandeh
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.